2012
DOI: 10.1016/j.bmcl.2012.01.095
|View full text |Cite
|
Sign up to set email alerts
|

Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain

Abstract: Four core structures capable of providing sub-nanomolar inhibitors of anthrax lethal factor (LF) were evaluated by comparing the potential for toxicity, physicochemical properties, in vitro ADME profiles, and relative efficacy in a rat lethal toxin (LT) model of LF intoxication. Poor efficacy in the rat LT model exhibited by the phenoxyacetic acid series (3) correlated with low rat microsome and plasma stability. Specific molecular interactions contributing to the high affinity of inhibitors with a secondary a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
22
0
3

Year Published

2013
2013
2018
2018

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 16 publications
(26 citation statements)
references
References 19 publications
1
22
0
3
Order By: Relevance
“…We previously described a series of small-molecule LFIs which possessed subnanomolar inhibitor constants (K i values) with demonstrated in vivo efficacy in the protection of rats against challenge with LT (23)(24)(25). In this work, we demonstrate that LFIs provide a significant survival benefit when used as a monotherapy and offer full protection when used in combination with subprotective doses of antibiotic or anti-EF monoclonal antibodies in a murine spore infection model.…”
Section: The Use Of Antibiotics Which Can Clear Active Infection By Bmentioning
confidence: 79%
See 1 more Smart Citation
“…We previously described a series of small-molecule LFIs which possessed subnanomolar inhibitor constants (K i values) with demonstrated in vivo efficacy in the protection of rats against challenge with LT (23)(24)(25). In this work, we demonstrate that LFIs provide a significant survival benefit when used as a monotherapy and offer full protection when used in combination with subprotective doses of antibiotic or anti-EF monoclonal antibodies in a murine spore infection model.…”
Section: The Use Of Antibiotics Which Can Clear Active Infection By Bmentioning
confidence: 79%
“…LFIs 8541 and 8420 have been previously described (24). The vehicle for LFI delivery was 4% dimethyl sulfoxide (DMSO)-10% polyethylene glycol (PEG) 400 in a phosphate-citrate buffer (0.1 M citric acid, 0.2 M Na 2 HPO 4 , pH 6.0).…”
Section: Methodsmentioning
confidence: 99%
“…Ингибиторы ЛФ III поколения разработаны на основе ранее идентифицированных молекул с использованием глубокого развития дизайна итеративного метода [39][40][41]. Эти ингибиторы уже обладают заметной протективной активностью in vivo [41].…”
Section: подходы к разработке специфических ингибиторов токсина сибирunclassified
“…Эти ингибиторы уже обладают заметной протективной активностью in vivo [41]. Применение данных ингибито-ров совместно с ингибиторами ЛФ продемонстрирова-ло интересный феномен кумулятивного действия этих молекул.…”
Section: подходы к разработке специфических ингибиторов токсина сибирunclassified
See 1 more Smart Citation